Aranesp Sales Data
| Rank 80 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Aranesp U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 80 ( 4) |
$203,664 | -3.03% | 247 | -4.63% |
| Q4 2012 | 76 (5) |
$210,027 | -4.44% | 259 | -4.78% |
| Q3 2012 | 71 (2) |
$219,796 | -1.51% | 272 | -3.55% |
| Q2 2012 | 69 ( 3) |
$223,161 | -3.66% | 282 | -3.75% |
| Q1 2012 | 72 (6) |
$231,643 | -5.86% | 293 | -7.86% |
| Q4 2011 | 66 (15) |
$246,056 | -6.07% | 318 | -3.64% |
| Q3 2011 | 51 (3) |
$261,967 | -10.25% | 330 | -11.29% |
| Q2 2011 | 48 (3) |
$291,873 | -1.03% | 372 | -1.33% |
| Q1 2011 | 51 | $294,912 |  |
377 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| June 24, 2011 | FDA Modifies Dosing Recommendations for Erythropoiesis-Stimulating Agents |
| October 19, 2010 | FDA Advisers Back Anemia Drugs for Kidney Patients |
| October 19, 2010 | FDA Panel Backs Anemia Drugs For Kidney Disease |
| February 16, 2010 | FDA Tightens Controls on Anemia Drugs |
| December 3, 2008 | FDA Issues Questions and Answers on Medication Guides for Erythropoiesis-stimulating Agents (ESAs). |
| September 26, 2008 | Anemia Drugs Linked to Stroke Study Deaths: FDA |
